The burgeoning landscape of medication for excess body fat and type 2 metabolic disorder is currently witnessing considerable excitement surrounding both retatrutide and tirzepatide. While both represent novel dual GIP and GLP-1 receptor agonists, significant differences in their pharmacological profiles and clinical study results are emerging. … Read More

Showing promise in the landscape of obesity management, retatrutide represents a distinct approach. Different from many current medications, retatrutide works as a double agonist, simultaneously engaging both glucagon-like peptide-1 (GLP-1) and glucose-sensitive insulinotropic polypeptide (GIP) receptors. The dual engagement encourages multiple … Read More